From serendipity to design: the evolution of drug development in oncology.

Although screening of natural products remains the major method of discovering new anticancer drugs, newer techniques of rational drug design, computer-aided drug design, and combinatorial synthesis promise to broaden the scope of compounds available for screening. Recent changes in Food and Drug Administration rules allow for accelerated approval of drugs for treating cancer and other life-threatening illnesses, although the three-phase process of clinical trials remains largely unchanged.

[1]  D. Kessler,et al.  Faster evaluation of vital drugs. , 1995, Scientific American.

[2]  M. Fukuoka,et al.  Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Barry A. Bunin,et al.  The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. P. Fodor,et al.  Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. , 1994, Journal of medicinal chemistry.

[5]  S. P. Fodor,et al.  Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. , 1994, Journal of medicinal chemistry.

[6]  R. Houghten,et al.  Acetalins: opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Brugge.  New intracellular targets for therapeutic drug design. , 1993, Science.

[8]  I. Kuntz,et al.  Structure-based discovery of inhibitors of thymidylate synthase. , 1993, Science.

[9]  M J Ratain,et al.  Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. , 1993, Journal of the National Cancer Institute.

[10]  N. Onetto,et al.  Drug discovery and development in the pharmaceutical industry. , 1992, Seminars in oncology.

[11]  I. Kuntz.  Structure-Based Strategies for Drug Design and Discovery , 1992, Science.

[12]  L V Rubinstein,et al.  Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. , 1992, Cancer research.

[13]  E. Kohn,et al.  In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. , 1992, Cancer research.

[14]  P. Loehrer.  Salvage therapy in recurrent germ cell cancer. , 1991, Hematology/oncology clinics of North America.

[15]  R. DiMarchi,et al.  The rapid identification of HIV protease inhibitors through the synthesis and screening of defined peptide mixtures. , 1991, Biochemical and biophysical research communications.

[16]  R. Houghten,et al.  Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery , 1991, Nature.

[17]  A. Greene,et al.  An improved synthesis of the taxol side chain and of RP 56976 , 1990 .

[18]  D. Kessler,et al.  The regulation of investigational drugs. , 1989, The New England journal of medicine.

[19]  I. Kuntz,et al.  Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. , 1988, Journal of medicinal chemistry.

[20]  R. Temple,et al.  Food and Drug Administration requirements for approval of new anticancer drugs. , 1985, Cancer treatment reports.

[21]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[22]  J. Clardy,et al.  Isolation and structure of bryostatin 1 , 1982 .

[23]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[24]  F. Schabel,et al.  Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. , 1980, Cancer research.

[25]  G M Crippen,et al.  Quantitative structure-activity relationships by distance geometry: systematic analysis of dihydrofolate reductase inhibitors. , 1980, Journal of medicinal chemistry.

[26]  T. Anderson,et al.  The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs. , 1973, International journal of clinical pharmacology, therapy and toxicology.

[27]  G. Ross,et al.  Primary chemotherapy of nonmetastatic trophoblastic disease in women. , 1963, American journal of obstetrics and gynecology.

[28]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[29]  Filov Va.  [Antineoplastic drug development: some results and perspectives]. , 1997 .

[30]  E K Rowinsky,et al.  Paclitaxel (taxol) , 1995, The New England journal of medicine.

[31]  H. Fujita.  [Anticancer drugs]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[32]  M. Grever,et al.  Cell line-based screening for new anticancer drugs , 1994 .

[33]  R. Cramer,et al.  Recent advances in comparative molecular field analysis (CoMFA). , 1989, Progress in clinical and biological research.

[34]  B. Chabner,et al.  Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.